Chapter 3

Moat and OTC Threat

The de-rating raised a fair question about whether Sonova's four-point margin step-down is cyclical or a permanent reset. The competitive evidence points to cyclical. Hearing care sits on a documented demographic tailwind (a 4–6% structural growth rate and adoption rates still in the single digits outside the developed world), the manufacturing end is a five-firm oligopoly, and Sonova gained share through the downturn on the strength of one product cycle. The live threat — over-the-counter devices and Apple's AirPods — is concentrated at the mild-loss end that prescription hearing care mostly does not serve.

A market that grows regardless of the cycle

The pool Sonova fishes in is expanding on demographics, not on any single company's execution. Demant, the closest pure-play rival, puts the long-run structural growth rate of the hearing-aid market at 4–6% per year in both units and value — roughly half from aging populations and half from rising adoption — with about 13 million people fitted with some 23 million devices in 2024 [1]. Amplifon, the largest retailer, frames the same demand: over 1.5 billion people live with some hearing loss, at least 430 million need rehabilitation today, rising to 700 million by 2050, against a global cost of untreated hearing loss it estimates near $1 trillion a year [2]. Sonova's own strategy leans on the same reading: demand expanding on aging and longer treatment horizons, with "persistently low adoption rates" leaving headroom across all regions, particularly Asia [3].

Sources: structural market growth per Demant FY2024 Annual Report [4]; annual cost of untreated hearing loss per Amplifon FY2025 Annual Report [5].

The unconverted demand is what makes the tailwind durable rather than a one-off recovery. Adoption — the share of the hearing-impaired who actually wear a device — runs around 32% in developed markets, roughly 9% in other developing economies, and about 2% in China and India, on Sonova's own market map [6]. Amplifon pegs adoption near 40% in high-income countries and 5–10% in emerging ones [7]. Either way, most people who need a hearing aid do not yet own one, and each cohort of new adopters is larger than the last.

Source: Sonova investor presentation, May 2024, Market potential [8].

The structure: a manufacturing oligopoly on top of a fragmented shop-front

The industry has two very different layers, and Sonova's advantage lives in the concentrated one. The wholesale hearing-aid market — the devices themselves — is roughly $7 billion a year and, in Demant's description, a field of "highly specialised players competing in very product-driven markets where significant R&D initiatives underpin market positions" [9]. Industry market research puts five manufacturers — WS Audiology, GN, Sonova, Starkey and Demant — at about 92% of that global manufacturing market in 2024, with WS Audiology the largest at roughly 27%. The retail layer is the opposite: a roughly $20 billion market of mostly independent, owner-operated clinics [10], where even Amplifon, the global leader, holds only about 13% share [11]. Sonova is one of a handful of firms that spans both: it manufactures under Phonak and Unitron and controls one of the largest owned retail networks through AudioNova.

That structure is what an entrant has to overcome, and it shows up in spending. Sonova put CHF 217.7 million into R&D in FY2026, about 6% of sales, and Demant spent a near-identical share of its revenue [12]. Neither figure is large next to a consumer-electronics giant, so raw R&D budget is not the barrier. The barrier is the combination that a device company alone cannot buy: a proprietary chip and audiology-algorithm stack, clinical validation, the fitting expertise of trained hearing-care professionals, and — in the prescription channel — bundled reimbursement arrangements with bodies such as the UK's National Health Service and the US Department of Veterans Affairs [13]. The switching cost sits with the patient: a moderate-to-severe device is fitted, tuned and serviced over years by a professional, which is a relationship, not a purchase.

The moat in the numbers: share gains through the downturn

An advantage only counts if it shows up in results. Sonova's did, at the worst point in the cycle. After launching the Phonak Audéo Infinio and Sphere Infinio platforms in August 2024 — built on a dedicated chip and deep-neural-network sound processing — the Hearing Instruments business grew 8.5% in local currency over FY2024/25 and accelerated to 9.8% in the second half, "consistently" taking share, even as a US private-market slowdown pressured volumes and pricing late in the year [14]. The share gains continued into the next year: Hearing Instruments grew 5.7% in local currency in the first half of FY2025/26, again ahead of the 4–6% market, which the company again attributed to sustained share gains [15].

Source: Sonova FY2024/25 results release [16] and 5.7% first-half local-currency growth per the H1 FY2025/26 Semi-Annual Report [17]. Structural market growth per Demant [18].

The margin compression that worried the market was also industry-wide, which is the clearest signal that it was cyclical. Demant's operating margin (before special items) fell from 20.9% in 2023 to 17.2% in 2025, and Amplifon's EBITDA margin slipped from 23.3% to 21.4% in a single year [19][20]. Sonova's normalized operating margin sits inside that same band — and, unlike the two pure-plays, has turned back up, from a 20.6% trough in FY2024 to 22.5% in FY2026 [21]. The reported franc EBIT margin stayed depressed largely because of the strong Swiss franc and the Sennheiser reclassification covered in Financials and Estimates, not because the underlying franchise weakened.

Sources: Sonova normalized EBITA margin in five-year key figures, Annual Report 2025/26 [22]; Demant EBIT margin before special items, FY2025 financial highlights [23]; Amplifon FY2025 financial review [24]. Fiscal bases and margin definitions differ across the three; Sonova's year ends 31 March, Demant and Amplifon report on calendar years.

Read as a set, the three make a coherent picture: the 2022–24 compression fell on the whole industry — post-pandemic normalization, a weak China market, a US private-market slowdown and heavy new-platform launch costs — and Sonova came through it with more share and a normalized margin that has already recovered, while the two closest peers were still declining in their latest year.

The OTC and Apple threat, in proportion

The disruption case names over-the-counter devices and, since Apple added a hearing-aid feature to AirPods Pro in late 2024, consumer electronics. The force of that threat depends on which hearing loss it reaches. On the World Health Organization data EssilorLuxottica reproduces, about 1,153 million of the 1.5 billion people with hearing loss have mild loss; moderate loss affects 266 million and moderately-severe-to-complete loss a further 164 million [25]. OTC devices, self-fitting earbuds and AirPods are cleared for perceived mild to moderate loss; the prescription market that Sonova serves is weighted toward the moderate-to-severe end, where the device has to be fitted and tuned to an audiogram.

Source: World Health Organization data as presented in EssilorLuxottica FY2025 Universal Registration Document [26].

So far the two markets look additive rather than substitutive. Demant, which has the most to lose, tells its own shareholders that OTC devices have "increase[d] general access to treating hearing loss" but that "their impact on the prescription hearing aid market in the US remains limited" — while adding the honest caveat that new form factors "could pose a risk to the prescription hearing aid market, if successful" [27]. Independent industry commentary in 2024–25 reached the same reading: OTC and AirPods have so far expanded awareness and the entry funnel rather than cannibalized fitted-device sales. Sonova itself plays both sides — it sells OTC self-fitting aids under Sennheiser in the US, China and Japan alongside its prescription range [28] — and its clearest statement of where it thinks the value is came from divesting that consumer-hearing business in 2026, the round-trip covered in Hearing's Fallen Leader. The company is concentrating on the professional channel, not retreating from it.

The threat that deserves more weight is quieter than Apple. Demant flags US managed-care consolidation as a genuine pressure on average selling prices, as volume concentrates among fewer, larger buyers able to push down fitting fees [29]. That is the mechanism already visible in Sonova's late-FY2025 US ASP softness [30], and it works on price rather than on whether people buy a fitted device at all. A well-capitalised new entrant is also now probing the mild end from a different direction: EssilorLuxottica launched Nuance Audio hearing eyewear in 2025, aimed at the same mild-to-moderate customer through an eyeglasses form factor.

What would change this read

The measured conclusion is that the competitive position strengthened during the de-rating rather than eroded, which places the margin step-down on the cyclical side of the ledger. The strongest fact against it is that the normalized-margin recovery leans heavily on one product cycle — the Infinio/Sphere launch — and product leadership in this industry rotates roughly every two to three years as rivals answer. The read would change if share gains reverse as Demant, WS Audiology and GN ship competitive platforms; if OTC or AirPods-class devices climb credibly into moderate loss rather than staying at the mild end; or if managed-care and channel pressure compress prescription ASPs faster than volume growth can offset. The line items that settle it are Hearing Instruments local-currency growth relative to the 4–6% market, the normalized EBITA margin trajectory off its FY2024 trough, and US ASP commentary in the half-year releases — each checkable in the next two reporting cycles.